Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 212Active not recruiting 113Not yet recruiting 65Completed 57Terminated 22Withdrawn 4Suspended 2Enrolling by invitation 2

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Uterine Cervical Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Ovarian Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 14Specimen Handling 13Cyclophosphamide 11fludarabine 10Radiotherapy 9Biopsy 9atezolizumab 7Nivolumab 7Radiation 6Gemcitabine 5fludarabine phosphate 4aldesleukin 4Prednisone 4Paclitaxel 4Etoposide 4Cytarabine 4Cisplatin 4Carboplatin 4Blood Specimen Collection 4Bevacizumab 4ALT-803 4venetoclax 3lenvatinib 3avelumab 3X-Rays 3Vincristine 3Surveys and Questionnaires 3Rituximab 3Phantoms, Imaging 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Bevacizumab × 1 year × Clear all
NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

NCT07146919 2026-04-23

ANGELICA

Centre Leon Berard

Phase 1/2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07323576 2026-02-09

INAVO-CRC

Hoffmann-La Roche

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡